Tenaya Therapeutics, Inc. (TNYA) stock
TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.32−0.01 (-3.24%)
Close on Nov 17, 2026Market cap $72.38MP/E –Yield –
Tenaya Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Tenaya Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $61.61M, down 20.5% year over year. For fiscal 2025 it was $68.61M, down 20.9% from the year before. The highest annual figure on record is $98.04M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.61M | -20.9% |
| FY2024 | Dec 31, 2024 | $86.74M | -11.5% |
| FY2023 | Dec 31, 2023 | $98.04M | +3.7% |
| FY2022 | Dec 31, 2022 | $94.54M | +73.8% |
| FY2021 | Dec 31, 2021 | $54.39M | +74.9% |
| FY2020 | Dec 31, 2020 | $31.10M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.60M | -4.4% |
| Q1 FY2026 | Mar 31, 2026 | $14.84M | -29.6% |
| Q4 FY2025 | Dec 31, 2025 | $14.80M | -20.8% |
| Q3 FY2025 | Sep 30, 2025 | $15.36M | -24.5% |
| Q2 FY2025 | Jun 30, 2025 | $17.37M | -23.3% |
| Q1 FY2025 | Mar 31, 2025 | $21.08M | -15.9% |
| Q4 FY2024 | Dec 31, 2024 | $18.69M | -18.3% |
| Q3 FY2024 | Sep 30, 2024 | $20.35M | -11.9% |
| Q2 FY2024 | Jun 30, 2024 | $22.65M | -14.5% |
| Q1 FY2024 | Mar 31, 2024 | $25.06M | -2.1% |
| Q4 FY2023 | Dec 31, 2023 | $22.87M | -11.2% |
| Q3 FY2023 | Sep 30, 2023 | $23.09M | -2.8% |
| Q2 FY2023 | Jun 30, 2023 | $26.48M | +26.8% |
| Q1 FY2023 | Mar 31, 2023 | $25.61M | +6.0% |
| Q4 FY2022 | Dec 31, 2022 | $25.75M | +22.9% |
| Q3 FY2022 | Sep 30, 2022 | $23.76M | +83.5% |
| Q2 FY2022 | Jun 30, 2022 | $20.88M | +91.4% |
| Q1 FY2022 | Mar 31, 2022 | $24.16M | +151.9% |
| Q4 FY2021 | Dec 31, 2021 | $20.95M | +150.5% |
| Q3 FY2021 | Sep 30, 2021 | $12.94M | +52.6% |
| Q2 FY2021 | Jun 30, 2021 | $10.91M | +56.7% |
| Q1 FY2021 | Mar 31, 2021 | $9.59M | – |
| Q4 FY2020 | Dec 31, 2020 | $8.36M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.48M | – |
| Q2 FY2020 | Jun 30, 2020 | $6.96M | – |
See a number that looks wrong?